News of Note—Dr. Reddy’s and FDA; Divi’s Labs plant cleared; SK Capital completes Perrigo API deal

News of note from pharma manufacturing.

> Dr. Reddy’s in a filing said it will ask the FDA to reinspect its formulations plant in Duvvada in 2018. Announcement (PDF)

> India’s Divi’s Laboratories said in a filing with the Bombay Stock Exhange that the FDA has issued an Establishment Inspection Report for its Unit-II in Visakhapatnam, which had earlier received a Form 483 with six observations. Release (PDF)

> SK Capital has completed its $110 million buyout of Perrigo’s API business. Release | FiercePharma article

Suggested Articles

With momentum building in Pfizer’s gene therapy programs, it has bought a building in North Carolina where it will consolidate clinical manufacturing.

Novartis has gotten out in front of an FDA, and its competitors, by halting worldwide distribution of its generic Zantac.

Roche has spent years reprioritizing its manufacturing spending, and as part of that process, it's exiting a small molecule site in Ireland.